110 related articles for article (PubMed ID: 21956472)
1. Current status and challenges of personalized treatment of cancer: view inspired by the workshop.
Souchelnytskyi S
Exp Oncol; 2011 Sep; 33(3):166-9. PubMed ID: 21956472
[No Abstract] [Full Text] [Related]
2. MicroRNAs: small but potent oncogenes or tumor suppressors.
Lee YS; Dutta A
Curr Opin Investig Drugs; 2006 Jun; 7(6):560-4. PubMed ID: 16784027
[TBL] [Abstract][Full Text] [Related]
3. Cancer-related forecast biomarkers: a topic in focus of the Worldwide Innovative Network in Personalized Cancer Medicine (WIN).
Schmitt M; Lazar V
Bioanalysis; 2010 May; 2(5):851-3. PubMed ID: 21083216
[No Abstract] [Full Text] [Related]
4. [Pdcd4 tumor suppressor: properties, functions, and their application to oncology].
Vikhreva PN; Shepelev MV; Korobko EV; Korobko IV
Mol Gen Mikrobiol Virusol; 2010; (2):3-11. PubMed ID: 20545042
[TBL] [Abstract][Full Text] [Related]
5. DNase1: a new personalized therapy for cancer?
Rosner K
Expert Rev Anticancer Ther; 2011 Jul; 11(7):981-4. PubMed ID: 21806320
[No Abstract] [Full Text] [Related]
6. The clinical potential and challenges of sequencing cancer genomes for personalized medical genomics.
Cloonan N; Waddell N; Grimmond SM
IDrugs; 2010 Nov; 13(11):778-81. PubMed ID: 21046525
[TBL] [Abstract][Full Text] [Related]
7. NF-kappaB: tumor promoter or suppressor?
Perkins ND
Trends Cell Biol; 2004 Feb; 14(2):64-9. PubMed ID: 15102437
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs in cancer: personalizing diagnosis and therapy.
Nana-Sinkam SP; Fabbri M; Croce CM
Ann N Y Acad Sci; 2010 Oct; 1210():25-33. PubMed ID: 20973796
[TBL] [Abstract][Full Text] [Related]
9. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care.
Roukos DH
Expert Rev Mol Diagn; 2010 Jan; 10(1):33-48. PubMed ID: 20014921
[TBL] [Abstract][Full Text] [Related]
10. Genomics, personalized medicine and cancer practice.
Dancey J
Clin Biochem; 2012 Apr; 45(6):379-81. PubMed ID: 22424082
[No Abstract] [Full Text] [Related]
11. MiRNAs as biomarkers and therapeutic targets in cancer.
Heneghan HM; Miller N; Kerin MJ
Curr Opin Pharmacol; 2010 Oct; 10(5):543-50. PubMed ID: 20541466
[TBL] [Abstract][Full Text] [Related]
12. Tumour suppression: putting on the brakes.
Harris H
Nature; 2004 Jan; 427(6971):201. PubMed ID: 14724616
[No Abstract] [Full Text] [Related]
13. Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management?
Roukos DH
Expert Rev Mol Diagn; 2010 Apr; 10(3):247-50. PubMed ID: 20370580
[No Abstract] [Full Text] [Related]
14. Control of autophagy by oncogenes and tumor suppressor genes.
Maiuri MC; Tasdemir E; Criollo A; Morselli E; Vicencio JM; Carnuccio R; Kroemer G
Cell Death Differ; 2009 Jan; 16(1):87-93. PubMed ID: 18806760
[TBL] [Abstract][Full Text] [Related]
15. Integrating germline and somatic data towards a personalized cancer medicine.
Pujana MA
Trends Mol Med; 2014 Aug; 20(8):413-5. PubMed ID: 25086750
[TBL] [Abstract][Full Text] [Related]
16. Is there a role of Eastern Europe in cancer biomarkers for personalized cancer medicine?
Berindan-Neagoe I; Paradiso A
Cancer Biomark; 2014; 14(2-3):85-6. PubMed ID: 24878808
[No Abstract] [Full Text] [Related]
17. Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma.
Imbeaud S; Ladeiro Y; Zucman-Rossi J
Semin Liver Dis; 2010 Feb; 30(1):75-86. PubMed ID: 20175035
[TBL] [Abstract][Full Text] [Related]
18. [Update: personalized diagnostics and therapies for pediatric cancer patients].
Eggert A
Klin Padiatr; 2013 May; 225(3):107-9. PubMed ID: 23716271
[No Abstract] [Full Text] [Related]
19. OncomiRs: the discovery and progress of microRNAs in cancers.
Cho WC
Mol Cancer; 2007 Sep; 6():60. PubMed ID: 17894887
[TBL] [Abstract][Full Text] [Related]
20. Snapshot: genetic mouse models of cancer.
Zender L; Zuber J; Lowe SW
Cell; 2007 May; 129(4):838. PubMed ID: 17512415
[No Abstract] [Full Text] [Related]
[Next] [New Search]
